Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2008

01-09-2008 | Research Paper

SOD derivatives prevent metastatic tumor growth aggravated by tumor removal

Authors: Kenji Hyoudou, Makiya Nishikawa, Yuki Kobayashi, Mai Ikemura, Fumiyoshi Yamashita, Mitsuru Hashida

Published in: Clinical & Experimental Metastasis | Issue 5/2008

Login to get access

Abstract

Although surgical removal is the most aggressive strategy to treat removable tumors, it sometimes aggravates tumor growth in metastatic sites. Because surgical procedures generate reactive oxygen species (ROS), known promoters of tumor metastasis and growth, we examined whether the growth of micrometastasis is inhibited by superoxide dismutase (SOD) derivatives after surgical removal of tumors in mice. Murine melanoma B16-BL6 cells were inoculated into the footpad to establish spontaneous pulmonary metastasis. The removal of the footpad tumor significantly (P < 0.05) increased the level of plasma lipoperoxides and the number of tumor cells in the lung. An intravenous injection of SOD or its pegylated-SOD derivative significantly (P < 0.05) inhibited the peroxidation and metastatic tumor growth. It also extended the survival period of mice undergoing removal of the footpad tumor. These findings indicate that the removal of tumor produces ROS, which then aggravates the growth of tumor cells in micrometastases. SOD derivatives can effectively prevent this metastatic tumor growth by detoxifying ROS.
Literature
1.
Crowley NJ, Seigler HF (1992) Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 127:1303–1308PubMed
2.
Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41:177–185PubMedCrossRef
3.
Goodison S, Kawai K, Hihara J, Jiang P, Yang M, Urquidi V, Hoffman RM, Tarin D (2003) Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 9:3808–3814PubMed
4.
Bouvy ND, Marquet RL, Jeekel J, Bonjer HJ (1997) Laparoscopic surgery is associated with less tumour growth stimulation than conventional surgery: an experimental study. Br J Surg 84:358–361PubMedCrossRef
5.
van den Tol PM, van Rossen EE, van Eijck CH, Bonthuis F, Marquet RL, Jeekel H (1998) Reduction of peritoneal trauma by using nonsurgical gauze leads to less implantation metastasis of spilled tumor cells. Ann Surg 227:242–248PubMedCrossRef
6.
Fukasawa M, Bryant SM, diZerega GS (1988) Superoxide anion production by postsurgical macrophages. J Surg Res 45:382–388PubMedCrossRef
7.
Kreinhoff U, Elmadfa I, Salomon F, Weidler B (1990) Antioxidant status after surgical stress. Infusionstherapie 17:261–267PubMed
8.
Zallen G, Moore EE, Johnson JL, Tamura DY, Aiboshi J, Biffl WL, Silliman CC (1999) Circulating postinjury neutrophils are primed for the release of proinflammatory cytokines. J Trauma 46:42–48PubMedCrossRef
9.
Murrell GA, Francis MJ, Bromley L (1990) Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 265:659–665PubMed
10.
Onoda JM, Piechocki MP, Honn KV (1992) Radiation-induced increase in expression of the alpha IIb beta 3 integrin in melanoma cells: effects on metastatic potential. Radiat Res 130:281–288PubMedCrossRef
11.
Shaughnessy SG, Whaley M, Lafrenie RM, Orr FW (1993) Walker 256 tumor cell degradation of extracellular matrices involves a latent gelatinase activated by reactive oxygen species. Arch Biochem Biophys 304:314–321PubMedCrossRef
12.
Sellak H, Franzini E, Hakim J, Pasquier C (1994) Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 83:2669–2677PubMed
13.
Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98:2572–2579PubMedCrossRef
14.
Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP (1996) Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98:1667–1675PubMedCrossRef
15.
Belkhiri A, Richards C, Whaley M, McQueen SA, Orr FW (1997) Increased expression of activated matrix metalloproteinase-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest 77:533–539PubMed
16.
Nishikawa M, Tamada A, Kumai H, Yamashita F, Hashida M (2002) Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer 99:474–479PubMedCrossRef
17.
Nishikawa M, Tamada A, Hyoudou K, Umeyama Y, Takahashi Y, Kobayashi Y, Kumai H, Ishida E, Staud F, Yabe Y, Takakura Y, Yamashita F, Hashida M (2004) Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin Exp Metastasis 21:213–221PubMedCrossRef
18.
Hyoudou K, Nishikawa M, Umeyama Y, Kobayashi Y, Yamashita F, Hashida M (2004) Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 10:7685–7691PubMedCrossRef
19.
Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M (2005) Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release 109:101–107PubMedCrossRef
20.
Nishikawa M, Hashida M (2006) Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opin Drug Deliv 3:355–369PubMedCrossRef
21.
Hyoudou K, Nishikawa M, Kobayashi Y, Kuramoto Y, Yamashita F, Hashida M (2006) Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clin Exp Metastasis 23:269–278PubMedCrossRef
22.
Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M (2006) PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med 41:1449–1458PubMedCrossRef
23.
Hyoudou K, Nishikawa M, Kobayashi Y, Kuramoto Y, Yamashita F, Hashida M (2007) Analysis of in vivo nuclear factor-kappaB activation during liver inflammation in mice: prevention by catalase delivery. Mol Pharmacol 71:446–453PubMedCrossRef
24.
Mihara K, Oka Y, Sawai K, Takakura Y, Hashida M (1994) Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol. J Drug Target 2:317–321PubMedCrossRef
25.
Yabe Y, Nishikawa M, Tamada A, Takakura Y, Hashida M (1999) Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J Pharmacol Exp Ther 289:1176–1184PubMed
26.
Poste G, Doll J, Hart IR, Fidler IJ (1980) In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40:1636–1644PubMed
27.
Yagi K (1976) A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15:212–216PubMedCrossRef
28.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328PubMedCrossRef
29.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285PubMedCrossRef
30.
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6PubMedCrossRef
Metadata
Title
SOD derivatives prevent metastatic tumor growth aggravated by tumor removal
Authors
Kenji Hyoudou
Makiya Nishikawa
Yuki Kobayashi
Mai Ikemura
Fumiyoshi Yamashita
Mitsuru Hashida
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9165-3

Other articles of this Issue 5/2008

Clinical & Experimental Metastasis 5/2008 Go to the issue

Research Paper

Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer

Research Paper

Single-cell tumor dormancy model of uveal melanoma

Research Paper

Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition

Research Paper

Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis

Research Paper

Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis

Research Paper

Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits